Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. 2002

Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8066, USA.

Both the beta-D-(+) and beta-L-(-)-enantiomers of 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D4FC) are clinically relevant compounds because of their potent anti-HIV and anti-HBV activities. Cross-resistance to L-D4FC with HBV containing a mutation in the conserved polymerase YMDD region has been observed. In order to better understand the effects of stereochemistry on planar 5-fluorinated cytidine analogs and to gain insight into resistance caused by YMDD mutations in HIV-1 reverse transcriptase (RT), a combination of transient kinetic studies and computer modeling were employed. In contrast to studies with the (+) and (-) isomers of 3TC-TP and FTC-TP, it was found that wild type RT had a high enantiomeric selectivity between the D-(+) and L-(-) isomers of D4FC-TP. While no resistance was conferred by the methionine 184 to valine mutation to D-D4FC-TP, L-D4FC-TP was incorporated 50- to 70-fold less efficiently. The kinetic parameters of incorporation in the presence of L-D4FC-TP by RT(WT) and the mechanism of resistance by RT(M184V) were found to be distinct from those seen with the corresponding L-isomers containing an oxathiolane ring: (-)-3TC-TP and (-)-FTC-TP. Molecular modeling suggests that L- and D-D4FC-TP are positioned in the active site favorably for incorporation by RT(WT) and that L-D4FC-TP, but not D-D4FC-TP, is sterically hindered by the addition of a beta branched amino acid at position 184 of RT(M184V).

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D003570 Cytidine Triphosphate Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. CTP,CRPPP,Magnesium CTP,Mg CTP,Triphosphate, Cytidine
D003845 Deoxycytosine Nucleotides Cytosine nucleotides which contain deoxyribose as the sugar moiety. Deoxycytidine Phosphates,Nucleotides, Deoxycytosine,Phosphates, Deoxycytidine
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170
D017354 Point Mutation A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair. Mutation, Point,Mutations, Point,Point Mutations

Related Publications

Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
January 2003, Antiviral chemistry & chemotherapy,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
March 1999, Journal of medicinal chemistry,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
February 1996, Protein expression and purification,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
September 2005, Antimicrobial agents and chemotherapy,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
July 1998, Antimicrobial agents and chemotherapy,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
December 2002, AIDS (London, England),
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
February 1999, Antimicrobial agents and chemotherapy,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
February 2009, European journal of medicinal chemistry,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
October 2008, The Journal of biological chemistry,
Adrian S Ray, and Eisuke Murakami, and Celeste N Peterson, and Junxing Shi, and Raymond F Schinazi, and Karen S Anderson
April 2001, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!